Images List Premium Download Classic

Steatohepatitis

Steatohepatitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Pharmaceutical compositions for combination therapy
Intercept Pharmaceuticals, Inc.
January 11, 2018 - N°20180008616

The present invention relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one lipid lowering agent (e. G., ppar-alpha agonist, ppar-delta agonist, ppar-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a fxr mediated disease or condition, such as primary biliary cirrhosis (...
Treatment for non-alcoholic fatty liver diseases
Dsm Ip Assets B.v.
January 04, 2018 - N°20180000775

The present invention relates to the use of mixtures of vitamin e and polyunsaturated fatty acids (pufas) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic ...
Co-agonists of the glucagon and glp-1 receptors
Merck Sharp & Dohme Corp.
December 21, 2017 - N°20170360893

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase iv (dpp-iv) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (glp-1) receptor and the glucagon (gcg) receptor, and the use of such glp-1 ...
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of treating liver diseases
Zafgen, Inc.
November 16, 2017 - N°20170326099

The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e. G., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2.
Methods and compositions for the treatment of non-alcoholic steatohepatitis
Vivus, Inc.
November 09, 2017 - N°20170319540

The present disclosure relates to methods of preventing, treating, delaying the onset of, and delaying the progression of liver disease by administering topiramate in combination with phentermine to a patient in need thereof.
Use of nalmefene in non-alcoholic steatohepatitis
Taiwanj Pharmaceuticals Co., Ltd.
October 26, 2017 - N°20170304294

The present invention relates to new medical uses of morphinans such as nalmefene and naltrexone and their related derivatives, pharmaceutical formulations thereof, and use thereof for prevention and treatment of nash, nafld, and/or ash.
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of lowering serum cholesterol
October 19, 2017 - N°20170296653

Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an il-10 agent are also provided.
Adeno-associated viral vectors for the gene therapy of metabolic diseases
Universitat Autonoma De Barcelona
October 12, 2017 - N°20170290926

The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors. The invention also relates to pharmaceutical compositions comprising said vectors.
Cenicriviroc for the treatment of fibrosis
Tobira Therapeutics ,inc.
August 24, 2017 - N°20170239262

The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvate thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (...
Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)
Nusirt Sciences, Inc.
August 24, 2017 - N°20170239253

Methods useful for sustaining a reduction of non-alcoholic steatohepatitis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or pde5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for ...
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting ...
Yale University
August 17, 2017 - N°20170232027

The invention includes a method of preventing or treating a toxic liver disease or disorder, such as but not limited to non-alcoholic steatohepatitis (nash), liver injury associated with or caused by alcohol consumption in a mammal afflicted with nash, alcoholic hepatitis, drug induced liver injury, primary sclerosing cholangitis, viral hepatitis, liver fibrosis, liver cirrhosis, and other toxic liver conditions, in ...
Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
Somalogic, Inc.
August 10, 2017 - N°20170227550

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (nash) are also provided.
Pharmaceutical compositions of berberine with epa and dha, and methods thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
May 18, 2017 - N°20170135995

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, ...
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of ...
Industry-academic Cooperation Foundation, Yonsei University
May 04, 2017 - N°20170121380

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a dlk1-fc fusion protein constructed by conjugation of an extracellular domain of dlk1 or a fragment thereof with a human antibody fc region. Also provided are health functional foods containing a dlk1-fc ...
Heterocyclic modulators of lipid synthesis
3-v Biosciences, Inc.
May 04, 2017 - N°20170119786

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis c infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (...
Thyromimetics for the treatment of fatty liver diseases
Metabasis Therapeutics, Inc.
April 27, 2017 - N°20170112864

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
Hadasit Medical Research Services And Development Ltd.
April 20, 2017 - N°20170105996

Methods of treating patients suffering from non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), including those also suffering front type ii diabetes mellitus (t2dm), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
Uses of mito-ob transgenic mice
University Of Manitoba
March 30, 2017 - N°20170089888

The mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes. It has been discovered that these mice also spontaneously develop nonalcoholic steatohepatitis (nash) and hepatocarcinogenesis over time. Also described is a mutant mito-ob mouse that develops lymphadenopathy and histiocytosis.
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
March 30, 2017 - N°20170087127

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
Novel compounds as diacylglycerol acyltransferase inhibitors
Glaxosmithkline Llc
March 23, 2017 - N°20170081342

This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of ...
Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use
March 23, 2017 - N°20170081280

Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions comprising the cysteine, n-acetylcysteine, and penicillamine related compounds, and methods of using cysteine, n-acetylcysteine, and penicillamine related compounds and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including paracetamol overdose, non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial ...
Loading